Physician profile
Robert M Cope
NPI 1891722245
$3,310.35
in general payments reported to CMS, 2019-2025
38 companies · $555 in 2025
The $555 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $465 · 2020: $209 · 2021: $434 · 2022: $498 · 2023: $491 · 2024: $658 · 2025: $555.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,704.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $523.70 | 2019-2025 | Spaceoar Vue System - 10ml, Rezum Generator, Spaceoar System |
| Abbvie INC. | $256.49 | 2022-2025 | Botox, Lupron Depot |
| Sumitomo Pharma America, INC. | $244.26 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $202.05 | 2019-2025 | Erleada |
| Laborie Medical Technologies Corp. | $191.32 | 2021-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Astellas Pharma US INC | $178.06 | 2019-2025 | Xtandi, Padcev |
| Procept Biorobotics Corporation | $164.36 | 2023-2025 | Aquabeam Robotic System |
| Pfizer INC. | $141.37 | 2019-2024 | |
| Dendreon Pharmaceuticals LLC | $135.92 | 2022-2025 | Provenge |
| Endo Pharmaceuticals INC. | $111.75 | 2019-2022 | |
| Calyxo, INC. | $99.95 | 2025 | Cvac Aspiration System |
| Amgen INC. | $81.49 | 2019-2022 | |
| 180 Medical, INC. | $78.69 | 2019-2022 | |
| Urovant Sciences INC | $75.76 | 2022 | |
| Myovant Sciences INC. | $71.55 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $70.59 | 2021 | |
| Myriad Genetic Laboratories, INC. | $65.56 | 2020-2024 | Prolaris |
| Astrazeneca Pharmaceuticals Lp | $62.88 | 2023 | Lynparza |
| Axonics, INC. | $61.55 | 2021-2024 | Axonics, Bulkamid |
| Bayer Healthcare Pharmaceuticals INC. | $52.87 | 2021-2025 | |
| Valencia Technologies Corporation | $48.39 | 2025 | Ecoin Device Kit |
| Medtronic USA, INC. | $41.16 | 2020 | |
| Allergan, INC. | $40.62 | 2019-2021 | |
| Tolmar Pharmaceuticals, INC. | $35.55 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $33.70 | 2024-2025 | Adstiladrin |
| Coloplast Corp | $33.31 | 2021-2024 | |
| Abc Home Medical Supply, INC. | $30.30 | 2024 | |
| Hitachi Healthcare Americas Corp. | $26.02 | 2019 | |
| Profound Medical Corp. | $23.35 | 2022 | |
| Halozyme INC | $20.48 | 2023 | |
| Immunitybio, INC. | $17.50 | 2025 | |
| Urogen Pharma, INC. | $16.13 | 2022 | |
| Cook Medical LLC | $15.62 | 2024 | Flexi-Tip |
| Travere Therapeutics, INC. | $15.12 | 2019 | |
| Integra Lifesciences Corporation | $15.05 | 2019 | |
| Dornier Medtech America, INC | $11.55 | 2020 | |
| Baudax Bio INC. | $11.29 | 2020 | |
| Microline Surgical INC | $5.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cope listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.